Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Post-Market Trading 11-15 17:04:03 EST

2.92

-0.13

-4.26%

盘后2.91

-0.01-0.34%

17:01 EST

High3.07	Low2.91	Vol1.92M
Open3.07	D1 Closing3.05	Amplitude5.25%
Mkt Cap435.32M	Tradable Cap416.10M	Total Shares149.08M
T/O5.70M	T/O Rate1.35%	Tradable Shares142.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":2.92,"timestamp":1731704400000,"preClose":3.05,"halted":0,"volume":1919960,"hourTrading":{"tag":"盘后","latestPrice":2.9101,"preClose":2.92,"latestTime":"17:01 EST","volume":19136,"amount":55867.8141632,"timestamp":1731708115225},"delay":0,"floatShares":142498947,"shares":149081461,"eps":-0.438272,"marketStatus":"Post-Market Trading","change":-0.13,"latestTime":"11-15 17:04:03 EST","open":3.07,"high":3.07,"low":2.91,"amount":5699987.999776,"amplitude":0.052459,"askPrice":3.08,"askSize":85,"bidPrice":2.9,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.438272,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1731718800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":3.05,"preHourTrading":{"tag":"盘前","latestPrice":3.06,"preClose":3.05,"latestTime":"09:29 EST","volume":1264,"amount":3807.0464031999995,"timestamp":1731680942092},"postHourTrading":{"tag":"盘后","latestPrice":2.9101,"preClose":2.92,"latestTime":"17:01 EST","volume":19136,"amount":55867.8141632,"timestamp":1731708115225},"volumeRatio":0.574594,"impliedVol":0.9709,"impliedVolPercentile":0.7659},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2482873924","title":"Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482873924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482873924?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:39","pubTimestamp":1731339540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 10:39 ET (15:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"1170797516","title":"Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1170797516","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170797516?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:28","pubTimestamp":1731328096,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc.  plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.Amsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.The stock had been trading around $3.4","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2482378330","title":"Piper Sandler Downgrades Xeris Biopharma to Neutral From Overweight, $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2482378330","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482378330?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:25","pubTimestamp":1731327925,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) has an average rating of Buy and price targets ranging from $3 to $6.60, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS"],"gpt_icon":0},{"id":"2482205155","title":"Xeris Biopharma downgraded to Neutral from Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2482205155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482205155?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:10","pubTimestamp":1731319844,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem downgraded Xeris Biopharma (XERS) to Neutral from Overweight with an unchanged price target of $3, post the Q3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-downgraded-to-neutral-from-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-downgraded-to-neutral-from-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2482289672","title":"Xeris Biopharma Holdings Inc : Piper Sandler Cuts to Neutral From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2482289672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482289672?lang=en_us&edition=fundamental","pubTime":"2024-11-11 12:47","pubTimestamp":1731300423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nFWN3MF2O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2482417473","title":"Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2482417473","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482417473?lang=en_us&edition=fundamental","pubTime":"2024-11-09 15:06","pubTimestamp":1731135971,"startTime":"0","endTime":"0","summary":"Total Revenue: $54.3 million, a 12% increase compared to the prior year.Net Product Revenue: $52.9 million, a 27% increase compared to the prior year.Year-to-Date Net Product Revenue: $139.6 million, a 26% increase compared to the prior year.Year-to-Date Total Revenue: $143 million, a 20% increase compared to the prior year.Recorlev Net Revenue: $17.7 million for the quarter, more than doubling compared to the prior year.Gvoke Net Revenue: $22.9 million for the quarter, a 29% increase compared to the prior year.Keveyis Net Revenue: $12.2 million for the quarter.Cash Position: Over $69 million at the end of the quarter.Cost of Goods Sold: 25.7% of total product revenue for the quarter.Research and Development Expenses: $5.9 million for the third quarter.Selling, General and Administrative Expenses: $45 million for the quarter, a 21% increase compared to the prior year.Revenue Guidance: Raised to $198 to $202 million for the year.GuruFocus has detected 5 Warning Signs with XERS.Xeris Bio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZW00nU381I61PSodKqgEIg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7d017290c2a9f1a3b0b5db2993e4f886","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZW00nU381I61PSodKqgEIg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7d017290c2a9f1a3b0b5db2993e4f886"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-070611455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2482048915","title":"Xeris Biopharma Holdings Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482048915","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482048915?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:24","pubTimestamp":1731083054,"startTime":"0","endTime":"0","summary":"* Xeris Biopharma Holdings Inc    reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"1168315264","title":"Stock Track | Xeris Pharmaceuticals Soars on Q3 Beat, Raised 2024 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1168315264","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168315264?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:05","pubTimestamp":1731078307,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc  soared over 5% in pre-market trading on November 8, 2024 after the biopharmaceutical company reported better-than-expected third quarter results and raised its full-year revenue guidance.For the third quarter, Xeris posted total revenue of $54.3 million, exceeding analysts' estimates of $51.4 million. The solid top-line growth was driven by strong demand for the company's key products - Gvoke, Recorlev and Keveyis.Gvoke, the ready-to-use glucagon for severe h","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2481954483","title":"Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481954483","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481954483?lang=en_us&edition=fundamental","pubTime":"2024-11-08 22:30","pubTimestamp":1731076210,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  reported $54.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.3%. EPS of -$0.06 for the same period compares to -$0.09 a year ago.The reported revenue represents a surprise of +5.09% over the Zacks Consensus Estimate of $51.64 million. With the consensus EPS estimate being -$0.09, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Product Revenue- Gvoke: $22.94 million versus $22.97 million estimated by four analysts on average.Product Revenue- Keveyis: $12.19 million versus $12.50 million estimated by four ana","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-q3-earnings-143010959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2481104926","title":"Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481104926","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481104926?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:10","pubTimestamp":1731071403,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Xeris Biopharma , which belongs to the Zacks Medical - Drugs industry, posted revenues of $54.27 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 5.09%. This compares to year-ago revenues of $48.32 million. The company has topped consensus revenue estimates two times over the last four quarters.Xeris Biopharma shares have added about 43% since the beginning of the year versus the S&P 500's gain of 25.2%.While Xeris Biopharma has outperformed the market so far this year, the question that comes to invest","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-reports-q3-131003367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"1181652532","title":"Stock Track | Xeris Pharmaceuticals Soars 6% Pre-Market on Q3 Beat, Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1181652532","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181652532?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:03","pubTimestamp":1731070995,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc  shares soared over 6% in pre-market trading on Wednesday after the company reported better-than-expected third-quarter results and raised its full-year revenue guidance. The biopharmaceutical firm posted a Q3 revenue of $54.3 million, exceeding analysts' estimates of $51.4 million, driven by strong demand for its products Gvoke, Recorlev and Keveyis.Xeris saw robust growth across its key products in Q3. Gvoke net revenue jumped 29% year-over-year to $22.9 million on ri","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2481171536","title":"BRIEF-Xeris Biopharma Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171536?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:26","pubTimestamp":1731068817,"startTime":"0","endTime":"0","summary":"Nov 8  - Xeris Biopharma Holdings Inc   :   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN & TIGHTENS YEAR-END CASH TO $68MLN - $72MLN   * XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLIONSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2481920179","title":"Xeris Pharmaceuticals GAAP EPS of -$0.11 misses by $0.02, revenue of $54.3M beats by $2.87M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481920179","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481920179?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:11","pubTimestamp":1731067886,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals press release  (NASDAQ:XERS): Q3  GAAP EPS of -$0.11  misses by $0.02.\nRevenue of $54.3M (+12.4% Y/Y)  beats by $2.87M.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4265158-xeris-pharmaceuticals-gaap-eps-of-0_11-misses-0_02-revenue-of-54_3m-beats-2_87m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["XERS"],"gpt_icon":0},{"id":"2481717951","title":"Xeris Biopharma: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481717951","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481717951?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:10","pubTimestamp":1731067816,"startTime":"0","endTime":"0","summary":"CHICAGO  — CHICAGO  — Xeris Biopharma Holdings, Inc.  on Friday reported a loss of $15.7 million in its third quarter.On a per-share basis, the Chicago-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 6 cents per share.The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share.The company posted revenue of $54.3 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $51.6 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-q3-earnings-snapshot-121016002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2481764711","title":"Xeris Biopharma Raises Its 2024 Revenue Guidance To $198M-$202M From The Previous Guidance Of $190M-$200M Versus Consensus Of $193.403M, Tightens Year-End Cash To $68M-$72M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481764711","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481764711?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:07","pubTimestamp":1731067671,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Raises Its 2024 Revenue Guidance To $198M-$202M From The Previous Guidance Of $190M-$200M Versus Consensus Of $193.403M, Tightens Year-End Cash To $68M-$72M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41840685/xeris-biopharma-raises-its-2024-revenue-guidance-to-198m-202m-from-the-previous-guidance-of-190m-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2481176947","title":"Xeris Biopharma Holdings Q3 2024 Adj EPS $(0.06) Beats $(0.09) Estimate, Sales $54.27M Beat $51.43M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481176947","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481176947?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:03","pubTimestamp":1731067386,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent.  The company reported quarterly sales of $54.27 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41840313/xeris-biopharma-holdings-q3-2024-adj-eps-0-06-beats-0-09-estimate-sales-54-27m-beat-51-43m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xeris Biopharma Holdings Q3 2024 Adj EPS $(0.06) Beats $(0.09) Estimate, Sales $54.27M Beat $51.43M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2481176874","title":"BRIEF-Xeris Biopharma Q3 Net Income USD -15.738 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481176874","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481176874?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067245,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Biopharma Q3 Net Income USD -15.738 Million\n\n\nNov 08 (Reuters) - Xeris Biopharma Q3 basic EPS USD -0.11.\n\nQ3 operating income USD -12.893 million\nQ3 product revenue USD 52.861 million vs. IBES estimate USD 51.4 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nPLX4151E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2481766771","title":"Xeris Biopharma Holdings: Raises FY Guidance of Total Net REV to $198 Mln - $202Mln & Tightens Year-End Cash to $68Mln - $72Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481766771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481766771?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA80V1Y0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2481600176","title":"Xeris Biopharma Holdings: Cash, Cash Equivalents, & Short-Term Investments at Sept 30, 2024 Was $69.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481600176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481600176?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA80V1Y0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2481717572","title":"Xeris Biopharma Q3 Basic EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2481717572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481717572?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nPLX4151E8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":-0.0923},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.1338},{"period":"6month","weight":0.5404},{"period":"1year","weight":1.0748},{"period":"ytd","weight":0.2979}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.186811},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069518},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.024057},{"month":8,"riseRate":0.571429,"avgChangeRate":0.160809},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.078859},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032117},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.001775},{"month":12,"riseRate":0.5,"avgChangeRate":0.047808}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}